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Abstract
D-ribose, a naturally occurring pentose carbohydrate, has been shown to replenish high- energy
phosphates following myocardial ischemia and high intensity, repetitive exercise. Human studies
have mainly involved short-term assessment, including potential toxicity. Reports describing
adverse effects of D-ribose with prolonged ingestion have been lacking. Therefore, this study
assessed the toxicity of extended consumption of D-ribose in healthy adults. Nineteen subjects
ingested 20 grams/Day (10 grams, twice a Day) of ribose with serial measurements of biochemical
and hematological parameters at Days 0, 7, and 14. No significant toxic changes over the 14-day
assessment period occurred in complete blood count, albumin, alkaline phosphatase, gamma
glutamyltransferase, alanine amiotransferase, and aspartate aminotransferase. However, D-ribose
did produce an asymptomatic, mild hypoglycemia of short duration. Uric acid levels increased at
Day 7, but decreased to baseline values by Day 14. D-ribose consumption for 14 days appears not
to produce significant toxic changes in both hematological and biochemical parameters in healthy
human volunteers.
Background
D-ribose, a naturally occurring pentose carbohydrate, has
shown benefits with negligible adverse effects. Pre-clinical
studies have demonstrated the recovery benefits in
depressed high-energy phosphates with D-ribose as well
as functional improvements in the myocardium following
ischemia and in isolated skeletal muscle [1-4]. Clinically,
congestive heart failure patients have experienced
improvements in their diastolic dysfunction, ventilatory
efficiency, a better quality of life, and improved physical
function activities when taking oral D-ribose [5-7]. The
benefits in sports medicine have not been as obvious.
When athletes were subjected to repetitive, high intensity
exercise, Hellsten, et al. [8] reported that D-ribose pro-
vided a recovery benefit in depressed muscular high-
energy phosphates in athletes subjected to repetitive, high
intensity exercise. Others have also reported the benefits
of D-ribose [9-13]. However, some studies did not find a
beneficial role of D-ribose in sports medicine. The incon-
sistent results found in these studies could primarily be
due to differences in study design [14-19]. Even so, ribose
continues to attract the interest of athletes.
Safety of supplements is important and changes in serum
biochemical and/or hematological markers could provide
an early indication of cellular toxicity. Published studies
on D-ribose have mainly centered on acute, short-term
investigations, ranging from hours to a few days
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chemical and hematological parameters in healthy adults
who consumed D-ribose for 14 days.
Methods
We investigated the potential toxicity in hematological
and biochemical markers during a 14-day supplementa-
tion of oral D-ribose. St. Cloud State University's Institu-
tional Review Board approved this study and informed,
written consent was obtained from each subject prior to
participation. Twenty-one healthy, non-diabetic, adult
subjects (19–25 years of age) were initially enrolled; how-
ever, only 19 subjects (12 males, 7 females) completed the
study. Each subject maintained their daily diet and rou-
tine exercise habits from interviews. Twenty grams of D-
ribose, mixed in water, was consumed in two equally
divided doses at breakfast and dinner mealtimes each day.
Venous blood samples were drawn from an antecubital
vein and assessed for hematological and biochemical lab-
oratory parameters at baseline and at Days 7 and 14 while
on D-ribose. Each blood sample was collected at an early
time period each day in a fasted state. The blood samples
were collected in the AM, using a Becton Dickinson Vacu-
tainer (Becton Dickinson, Inc., Franklin Lakes, NJ) coated
with lithium heparin. All samples were collected at room
temperature (23°C), and each tube was initially frozen
before undergoing subsequent duplicate analyses. Meas-
ured parameters included: complete blood count (CBC,
including hemoglobin (Hgb), hematocrit (Hct), white
blood count (WBC), platelet counts (Plts), albumin, alka-
line phosphatase (ALKP), gamma glutamyltransferase
(GGT), alanine aminotransferase (ALT), aspartate ami-
notransferase (AST), uric acid, and glucose levels. Com-
plete blood counts were analyzed using a Coulter
Counter. Plasma samples were analyzed for albumin
(Johnson & Johnson Vitros II), glucose (YSI 2300 Stat
Analyzer), ALKP (Johnson & Johnson Vitros II), GGT
(Johnson & Johnson Vitros II), ALT (Johnson & Johnson
Vitros II), AST (Johnson & Johnson Vitros II), and uric
acid (Uric Acid Kit, Sigma Chemicals) levels.
Measured parameters, including duplicate assessments,
were analyzed by Analysis of Variance (ANOVA). Inde-
pendent variables, such as gender, were also statistically
analyzed by ANOVA. An accepted alpha level of signifi-
cance was 0.05. Analyses (mean ± SD) were performed
with MINITAB 12.1 (Minitab Incorporated, PA).
Results
There were no adverse physical symptoms in the 19 sub-
jects completing the study. There were no statistically sig-
nificant differences from baseline to the Day 7 and 14
evaluations in all subjects for CBC parameters: Hgb, Day
7(p < 0.44), Day 14 (p < 0.31); Hct, Day 7 (p < 0.3), Day
14 (p < 0.41); WBC, Day 7 (p < 0.30), Day 14 (p < 0.44);
Plts, Day 7 (p < 0.25), Day 14 (p < 0.40) (Table 1). Fur-
ther, there were no significant differences between gen-
ders in measured CBC parameters. However, there was a
slight decrease in WBC levels in all subjects with a greater
decrease in females at Day 14.
Albumin, ALKP, AST, ALT, GGT levels, with significance
are presented in Table 2. Plasma glucose and uric acid lev-
els are presented in figures 1 and 2. There were no signifi-
cant differences from baseline compared to Days 7 and 14
values of plasma glucose levels (p < 0.41 and p < 0.14,
respectively) and uric acid levels (p < 0.40 and p < 0.28,
respectively). No significant differences were found at Day
7 in the ALKP (p < 0.41), GGT (p < 0.03), ALT (p < 0.06),
AST (p < 0.11), and plasma glucose levels (p < 0.41).
However, at Day 7 there were slight elevations from base-
line values in AST and uric acid measurements. This
observed elevation in both AST and uric acid levels at Day
Table 1: Hematological Parameters. (Mean ± SD with p value significance for all subjects)
Hgb (grams/dL) Hct (%) WBC (103/uL) Plts (103/uL)
Males
Baseline 15.4 ± 0.56 45.4 ± 1.70 6.13 ± 0.82 235 ± 55.10
Day 7 15.1 ± 0.87 44.9 ± 0.90 6.29 ± 1.13 242 ± 62.41
Day 14 15.1 ± 0.69 44.7 ± 2.03 6.25 ± 1.06 246 ± 60.43
Females
Baseline 13.3 ± 0.45 39.5 ± 1.07 6.22 ± 1.64 236 ± 36.81
Day 7 13.3 ± 0.52 39.7 ± 1.21 6.10 ± 0.82 230 ± 48.05
Day 14 13.5 ± 0.60 40.1 ± 2.21 5.69 ± 1.17 232 ± 31.96
All Subjects
Baseline 14.3 ± 1.14 42.5 ± 3.26 6.18 ± 1.14 235 ± 48.03
Day 7 14.2 ± 1.17 42.2 ± 3.48 6.19 ± 1.01 236 ± 56.42
Day 14 14.3 ± 1.01 42.4 ± 3.09 5.97 ± 1.10 239 ± 51.18
p values
At Day 7 p < 0.44 p < 0.39 p < 0.30 p < 0.25
At Day 14 p < 0.31 p < 0.41 p < 0.44 p < 0.40Page 2 of 5
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ured plasma glucose levels, even though not statistically
significant at Day 7 (p < 0.41) and at Day 14 (p < 0.14),
and fell over the 14-Day study period (3.64 ± 0.80, 3.55 ±
0.85, 3.23 ± 1.03 mM/L) without clinical symptoms.
Assessment of biochemical parameters between genders
revealed no significant differences during the 14 days for
both albumin (p < 0.27) and ALT (p < 0.31). There was no
difference in ALKP in males; however, females demon-
strated a slight increase at Day 14, which appeared to
account for the noted increase in all subjects at the end of
the study endpoint (Table 2). Measured GGT levels
slightly decreased in males, unlike the slight increase
found in females at Day 7; however these levels were com-
parable to baseline by Day 14. Measured AST levels dem-
onstrated a potentially increasing trend (p < 0.11)
throughout the study in males. Female AST values
increased at Day 7 and fell by Day 14.
Uric acid levels were elevated without significance (p <
0.40) in all subjects at Day 7 with females demonstrating
less of an increase than males. However, the observed ele-
vated uric acid levels in all subjects at Day 7 declined by
Day 14. Both genders demonstrated a decrease in serum
glucose levels over the study.
Discussion
The safety of oral D-ribose has been reported in acute set-
tings in humans with no significantly adverse effects;
however, a drop in plasma glucose levels is common.
Segal and Foley [21,22] found different levels of hypogly-
cemia with D-ribose supplementation depending upon
dose with higher doses producing a greater decrease.
Gross et al. [23] has published similar findings. In nine
healthy subjects (8 males, 1 female, 23–37 years of age),
D-ribose doses of 83.3, 166.7 and 222.2 mg/kg/hr were
given for at least 4 hours, both orally and intravenously,
with serum ribose levels increasing in a dose-dependent
manner (maximum concentration of 75–85 mg/dl). A
166.7 mg/kg/hr of D-ribose resulted in a 25% reduction
Table 2: Liver Function Parameters. (Mean ± SD with p value significance for all subjects)
ALB (grams/dL) ALK P (U/L) AST (U/L) ALT (U/L) GGT (U/L)
Males
Baseline 5.077 ± 0.02 70.2 ± 20.06 21.3 ± 6.08 28.4 ± 6.79 27.6 ± 15.18
Day 7 5.087 ± 0.04 70.4 ± 19.74 19.6 ± 8.50 28.8 ± 6.55 22.7 ± 9.55
Day 14 5.078 ± 0.03 70.8 ± 20.41 25.6 ± 8.90 28.3 ± 11.79 25.4 ± 13.82
Females
Baseline 5.065 ± 0.01 63.6 ± 12.23 12.4 ± 3.21 20.6 ± 5.74 14.9 ± 3.29
Day 7 5.075 ± 0.02 64.4 ± 9.00 19.6 ± 9.98 19.4 ± 7.98 15.0 ± 3.51
Day 14 5.076 ± 0.03 67.7 ± 10.44 15.7 ± 5.68 20.3 ± 6.24 15.1 ± 3.48
All
Baseline 5.073 ± 0.02 66.9 ± 17.51 16.9 ± 6.75 24.5 ± 7.37 21.2 ± 13.57
Day 7 5.082 ± 0.03 67.4 ± 16.55 21.8 ± 9.06 24.1 ± 8.29 18.3 ± 8.62
Day 14 5.077 ± 0.02 69.2 ± 17.12 20.6 ± 9.11 24.3 ± 10.65 20.3 ± 12.11
p values
At Day 7 p < 0.01 p < 0.41 p < 0.11 p < 0.06 p < 0.03
At Day 14 p < 0.27 p < 0.46 p < 0.11 p < 0.31 p < 0.08
Glucose levels over study durationFigure 1
Glucose levels over study duration. bars represent 
standard deviation.
Uric Acid levels over study durationFigure 2
Uric Acid levels over study duration. bars represent 
standard deivation.Page 3 of 5
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increase in serum insulin concentration (mean: 8.4 to10.4
uU/ml). The variations in insulin levels were acute; and
did not solely account for the persistent hypoglycemia.
Fenstad et al. [24] concurred that D-ribose's affected on
plasma glucose values was dose dependent. Oral D-ribose
doses of 5 and 10 grams produced an acute state of
hypoglycemia (mean values: 3.08 and 2.77 mmol/L,
respectively), which returned to baseline values approxi-
mately 2 hours post consumption. Insulin levels revealed
an initial increased spike (3.0–3.6 uIU), peaking at 15
min post ingestion, and returning to relative baseline val-
ues by 45–60 min post consumption. Our study involving
the extended supplementation of D-ribose concurs with
previous published reports that even a longer duration of
oral consumption results in a state of asymptomatic
hypoglycemia.
Fenstad et al. [24] also found that D-ribose (5 and 10
grams/oral dose) produced an increase in uric acid levels.
In our study involving a longer consumption period, ele-
vated levels of uric acid, peaking at Day 7 and then trend-
ing toward baseline by Day 14 were observed. Uric acid
production occurs due to the synthesis of purine nucle-
otides, degraded through regulated reactions. The net
increase in uric acid levels may result from an increase in
de novo purine synthesis with a concomitant enhance-
ment in purine nucleotide degradation [25]. Yamaoka
and Itakura [26] reported that purine nucleotide biosyn-
thesis is regulated by amidophosphoribosyltransferase
and phosphoribosyl-pyrophosphate synthetase in the de
novo pathway. Accelerated biosynthesis, catabolism of
purine nucleotides or decrease in urinary excretion, could
all potentially account for this hyperuricemia. Further,
ribose combining with adenine, producing adenosine,
could enhance catabolism with increasing production of
uric acid when ingesting ribose.
Individuals have occasionally experienced mild gastroin-
testinal symptoms, such as nausea, loose stools, or rare
bouts of diarrhea [20,27]. Pliml et al. [20] stated that
some patients experienced mild gastrointestinal symp-
toms, such as nausea and diarrhea; although a dose of 60
grams/day was used in that study. Our subjects did not
experience any gastrointestinal problems with a dose of
20 grams per day. Recommended doses for D-ribose in
the literature range between 5–7 grams and the 10 gram
dose in our study did not produce any adverse gastrointes-
tinal maladies.
There are few reports on adverse laboratory values with D-
ribose in animals. D-ribose (0, 5, 10, 20%) fed to Wistar
rats for 13 weeks revealed a significant decrease in choles-
terol, triglycerides and phospholipid levels with signifi-
cant increases in liver function tests of alkaline
phosphatase, aspartate aminotransferase, and albumin/
globulin ratio, without abnormal histopathological find-
ings [28]. Griffiths et al. [28] also reported no significant
changes in measured CBC parameters; however, there was
a significant increase in neutrophils with a significant
reduction in lymphocytes. We found no significant abnor-
mal hepatic values or significant abnormalities in hema-
tological parameters with extended oral consumption of
D-ribose in healthy individuals.
Conclusion
In summary, 20 grams of oral D-ribose/day for 14-days in
healthy subjects did not elicit significant adverse hemato-
logical or biochemical abnormalities. However, a mild
state of hypoglycemia and hyperuricemia can be observed
after oral consumption.
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